98 related articles for article (PubMed ID: 1406908)
1. Assessment of buprenorphine in a drug discrimination procedure in humans.
Bigelow GE; Preston KL
NIDA Res Monogr; 1992; 121():28-37. PubMed ID: 1406908
[TBL] [Abstract][Full Text] [Related]
2. Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure.
Jones HE; Bigelow GE; Preston KL
J Pharmacol Exp Ther; 1999 Jun; 289(3):1350-61. PubMed ID: 10336526
[TBL] [Abstract][Full Text] [Related]
3. Drug discrimination assessment of agonist-antagonist opioids in humans: a three-choice saline-hydromorphone-butorphanol procedure.
Preston KL; Bigelow GE
J Pharmacol Exp Ther; 1994 Oct; 271(1):48-60. PubMed ID: 7525929
[TBL] [Abstract][Full Text] [Related]
4. Drug discrimination in human postaddicts: agonist-antagonist opioids.
Preston KL; Bigelow GE; Bickel WK; Liebson IA
J Pharmacol Exp Ther; 1989 Jul; 250(1):184-96. PubMed ID: 2473187
[TBL] [Abstract][Full Text] [Related]
5. Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination.
Preston KL; Liebson IA; Bigelow GE
J Pharmacol Exp Ther; 1992 Apr; 261(1):62-71. PubMed ID: 1373189
[TBL] [Abstract][Full Text] [Related]
6. Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination.
Preston KL; Bigelow GE
J Pharmacol Exp Ther; 2000 Oct; 295(1):114-24. PubMed ID: 10991968
[TBL] [Abstract][Full Text] [Related]
7. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers.
Strain EC; Preston KL; Liebson IA; Bigelow GE
J Pharmacol Exp Ther; 1992 Jun; 261(3):985-93. PubMed ID: 1376362
[TBL] [Abstract][Full Text] [Related]
8. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.
Bickel WK; Stitzer ML; Bigelow GE; Liebson IA; Jasinski DR; Johnson RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):47-53. PubMed ID: 2459370
[TBL] [Abstract][Full Text] [Related]
9. Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists.
Picker MJ; Benyas S; Horwitz JA; Thompson K; Mathewson C; Smith MA
J Pharmacol Exp Ther; 1996 Dec; 279(3):1130-41. PubMed ID: 8968334
[TBL] [Abstract][Full Text] [Related]
10. Discriminative stimulus effects of acute morphine followed by naltrexone in the squirrel monkey: a further characterization.
White DA; Holtzman SG
J Pharmacol Exp Ther; 2005 Jul; 314(1):374-82. PubMed ID: 15843500
[TBL] [Abstract][Full Text] [Related]
11. Three-choice drug discrimination in opioid-dependent humans: hydromorphone, naloxone and saline.
Preston KL; Bigelow GE; Bickel W; Liebson IA
J Pharmacol Exp Ther; 1987 Dec; 243(3):1002-9. PubMed ID: 2447262
[TBL] [Abstract][Full Text] [Related]
12. Precipitated withdrawal by pentazocine in methadone-maintained volunteers.
Strain EC; Preston KL; Liebson IA; Bigelow GE
J Pharmacol Exp Ther; 1993 Nov; 267(2):624-34. PubMed ID: 7504098
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
Strain EC; Preston KL; Liebson IA; Bigelow GE
J Pharmacol Exp Ther; 1995 Feb; 272(2):628-38. PubMed ID: 7853176
[TBL] [Abstract][Full Text] [Related]
14. Acute administration of buprenorphine in humans: partial agonist and blockade effects.
Walsh SL; Preston KL; Bigelow GE; Stitzer ML
J Pharmacol Exp Ther; 1995 Jul; 274(1):361-72. PubMed ID: 7542336
[TBL] [Abstract][Full Text] [Related]
15. Discriminative stimulus effects of buprenorphine in the rat.
Holtzman SG
Psychopharmacology (Berl); 1997 Apr; 130(3):292-9. PubMed ID: 9151365
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the discriminative stimulus effects of buprenorphine in pigeons.
Galici R; Brandt MR; France CP
Psychopharmacology (Berl); 2002 Mar; 160(2):132-9. PubMed ID: 11875630
[TBL] [Abstract][Full Text] [Related]
17. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
18. Opioid drug discrimination in humans: stability, specificity and relation to self-reported drug effect.
Bickel WK; Bigelow GE; Preston KL; Liebson IA
J Pharmacol Exp Ther; 1989 Dec; 251(3):1053-63. PubMed ID: 2481029
[TBL] [Abstract][Full Text] [Related]
19. Discriminative stimulus effects of opioids in pigeons trained to discriminate fentanyl, bremazocine and water: evidence of pharmacological selectivity.
Picker MJ; Cook CD
Behav Pharmacol; 1997 Jun; 8(2-3):160-73. PubMed ID: 9833011
[TBL] [Abstract][Full Text] [Related]
20. Discriminative stimulus effects of reversible and irreversible opiate agonists: morphine, oxymorphazone and buprenorphine.
France CP; Jacobson AE; Woods JH
J Pharmacol Exp Ther; 1984 Sep; 230(3):652-7. PubMed ID: 6206224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
